Whether Enhertu Inj 100mg, Ilaris Injection Sol, and the morning sickness drugs that had passed the Health Insurance Review and Assessment Service's Drug Reimbursement Evaluation Committee review on the 1st, will be listed for reimbursement in April is gaining attention.

As all three drugs are highly sought-after by patients and the public, the government is trying to get them on the reimbursement list ahead of the 22nd National Assembly election scheduled on April 10.

According to industry sources on April 13, the companies for Enhertu Inj 100 mg (trastuzumab deruxtecan), Ilaris Injection Sol (canakinumab), and morning sickness drugs (doxylamine succinate + pyridoxine hydrochlo